Article

Quality of Life Maintained With Abemaciclib Plus Trastuzumab With or Without Fulvestrant in Patients with HR-Positive, HER2-Negative Breast Cancer

Abemacilib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for hormone receptor, human epidermal growth factor receptor 2 metastatic breast cancer.

Quality of life was maintained for patient-reported pain, global health, functioning, and most symptoms when abemaciblib was added to a trastuzumab and fulvestrant combination compared with the standard of care chemotherapy in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2-positive) advanced breast cancer (ABC).

The results were published as a poster session during the San Antonio Breast Cancer Symposium in San Antonio, TX. In the randomized, 3-arm, phase 2 study monarcHER study for HR-positive, HER2-positive ABC, abemaciclib in combination with trastuzumab and fulvestrant significantly improved investigator-assessed progression-free survival versus trastuzumab plus chemotherapy.

In the study, 237 postmenopausal (surgical, natural, or chemical ovarian suppression) women with ABC prior to HER2-positive directed therapies in the advanced setting were randomized 1:1:1 to 150 mg abemaciclib + trastuzumab (intravenous infusion every 21 days) with 500 mg fulvestrant or without fulvestrant vs trastuzumab plus physician’s choice of chemotherapy. Patient-reported outcomes were measured at baseline and at every cycle using the modified Brief Pain inventory-short form and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30.

Abemacilib is an oral selective inhibitor of cyclin-dependent kinases 4 and 6 approved for HR-positive, HER2-negative metastatic breast cancer.

Patient-reported outcome compliance rates were 90% through cycle 15. The range for median duration of each treatment component of each group was 7.5-10.0 cycles. No statistically significantly differences or clinically meaningful changes from baseline differences were observed between treatment groups for global health score, function scales, or for symptoms of fatigue, dyspnea, appetite loss, or financial difficulties. Worsening adverse events (AEs), including nausea/vomiting and diarrhea, showed statistically significant improvements with the fulvestrant plus trastuzumab group versus chemotherapy.

Overall, quality of life was maintained for patient-reported pain, global health, functioning, and most symptoms when abemaciclib was added to fulvestrant plus trastuzumab compared with physician’s choice of chemotherapy in patients with HR-positive, HER2-positive ABC. Furthermore, gastrointestinal-related adverse events were transient and consistent with the manageable, reversible AE profile.

REFERENCE

Health-related quality of life (HRQoL) in monarcHER: Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in HR+, HER2+ advanced breast cancer. Accessed December 2, 2019. https://plan.core-apps.com/sabcs2019/abstract/a25f48e96f590da9de0d7c903eddc944.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com